RESUMEN
BACKGROUND: Mass drug administration (MDA) has the potential to interrupt malaria transmission and has been suggested as a tool for malaria elimination in low-endemic settings. This study aimed to determine the effectiveness and safety of two rounds of MDA in Zanzibar, a pre-elimination setting. METHODS: A cluster randomised controlled trial was conducted in 16 areas considered as malaria hotspots, with an annual parasite index of > 0.8%. The areas were randomised to eight intervention and eight control clusters. The intervention included two rounds of MDA with dihydroartemisinin-piperaquine and single low-dose primaquine 4 weeks apart in May-June 2016. Primary and secondary outcomes were cumulative confirmed malaria case incidences 6 months post-MDA and parasite prevalences determined by PCR 3 months post-MDA. Additional outcomes included intervention coverage, treatment adherence, occurrence of adverse events, and cumulative incidences 3, 12, and 16 months post-MDA. RESULTS: Intervention coverage was 91.0% (9959/10944) and 87.7% (9355/10666) in the first and second rounds, respectively; self-reported adherence was 82.0% (881/1136) and 93.7% (985/1196). Adverse events were reported in 11.6% (147/1268) and 3.2% (37/1143) of post-MDA survey respondents after both rounds respectively. No serious adverse event was reported. No difference in cumulative malaria case incidence was observed between the control and intervention arms 6 months post-MDA (4.2 and 3.9 per 1000 population; p = 0.94). Neither was there a difference in PCR-determined parasite prevalences 3 months post-MDA (1.4% and 1.7%; OR = 1.0, p = 0.94), although having received at least the first MDA was associated with reduced odds of malaria infection (aOR = 0.35; p = 0.02). Among confirmed malaria cases at health facilities, 26.0% and 26.3% reported recent travel outside Zanzibar in the intervention and control shehias (aOR ≥ 85; p ≤ 0.001). CONCLUSIONS: MDA was implemented with high coverage, adherence, and tolerability. Despite this, no significant impact on transmission was observed. The findings suggest that two rounds of MDA in a single year may not be sufficient for a sustained impact on transmission in a pre-elimination setting, especially when the MDA impact is restricted by imported malaria. Importantly, this study adds to the limited evidence for the use of MDA in low transmission settings in sub-Saharan Africa. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02721186 (registration date: March 29, 2016).
Asunto(s)
Antimaláricos/administración & dosificación , Malaria/prevención & control , Malaria/transmisión , Administración Masiva de Medicamentos/métodos , Artemisininas/administración & dosificación , Femenino , Humanos , Incidencia , Malaria/epidemiología , Masculino , Prevalencia , Primaquina/administración & dosificación , Quinolinas/administración & dosificación , TanzaníaRESUMEN
BACKGROUND: The aim of this study was to assess cancer awareness among medical students in Saudi Arabia toward tobacco and alcohol use as risk factors. MATERIALS AND METHODS: A cross-sectional survey from October to December 2014, covering 1200 medical students, was performed. RESULTS: Of the total, 975 (81.25%) responded. The male to female ratio was 1.00:7.125. 96/975 (9.8%) had smoked tobacco in their lifetime, and 51/975 (5.23%) were alcoholic beverage consumers. On asking them whether tobacco smoking and alcohol consumption can cause cancer, only 4/975 (0.4%) and 14/975 (1.43%) answered no for smoking and alcohol, respectively. CONCLUSIONS: The prevalence of smoking and alcohol use is very low among medical students, which might be due to high female contribution besides social stigma. The prevalence of second-hand smoke (SHS) was found to be very high in Hail region.
Asunto(s)
Consumo de Bebidas Alcohólicas/epidemiología , Conocimientos, Actitudes y Práctica en Salud , Neoplasias/etiología , Fumar/epidemiología , Estudiantes de Medicina/psicología , Adulto , Consumo de Bebidas Alcohólicas/efectos adversos , Estudios Transversales , Femenino , Humanos , Masculino , Factores de Riesgo , Arabia Saudita/epidemiología , Fumar/efectos adversos , Encuestas y Cuestionarios , Contaminación por Humo de Tabaco , Adulto JovenRESUMEN
The present study was conducted to investigate the efficacy of sodium dichloroisocyanurate (NaDCC) on the infective stages of common food-borne intestinal protozoa; Entamoeba histolytica (E. histolytica), Giardia lamblia (G. lamblia), Cryptosporidium, Cyclospora and Microsporidia; beside its effect on raw green vegetables and fruits. Parasites, isolated from stool of patients with diarrhea or dysentery, were exposed to NaDCC solution (1g/l) for one and two hours. Disinfection effect of NaDCC was assessed by in-vitro viability, using trypan blue stain, and infectivity bioassay in laboratory animals as indicated by fecal and intestinal parasitic counts. Raw vegetables and fruits were dipped in NaDCC solution in the same concentration and exposure time as used for treatment of the parasites. Results revealed statistically significant reductions in viability and infectivity of all examined parasites indicating their susceptibility to NaDCC. Relative variations in susceptibility were revealed; E. histolytica and G. lamblia were most susceptible (100% reduction) followed by Microsporidia then Cryptospridium and Cyclospora. NaDCC did not affect the consistency, color, taste or flavor of raw green vegetables and fruits. The proved efficacy of NaDCC, in cheap and convenient dry tablet form, makes it a promising tool in decontaminating raw vegetables and fruits from food-borne protozoan parasites at household and restaurant levels as well as in catering and fresh produce industry. It is also recommended for disinfection of food preparation surfaces and equipment.
Asunto(s)
Coccidios/efectos de los fármacos , Entamoeba/efectos de los fármacos , Parasitología de Alimentos , Giardia lamblia/efectos de los fármacos , Triazinas/farmacología , DesinfectantesRESUMEN
The present study evaluated the effect of microwave irradiation on infective larvae of Trichinella spiralis (T. spiralis) by the ultrastructure changes of the microwaved larvae (ML) using scanning electron microscope (SEM). The ML tested the ability to immunize mice against a challenge infection with T. spiralis. For the optimal dose and the best route of immunization inducing protection against challenge infection, two doses were used; 300 & 600 ML as one or two-dose regimen, each dose was given orally and intraperitoneally (IP). SEM revealed tegumental damage of the ML in the form of distortion, loss of normal fold pattern and depressions or papillae protruded from their outer surface. After administration of the ML (orally or IP) to the non-infected control mice, neither adults nor larvae were detected in the intestines or muscles respectively. This indicated loss of larvae infectivity after exposure to the microwave irradiation. Also, a significant protection against challenge infection with T. spiralis was demonstrated in experimental mice immunized by ML, orally or IP. This was assessed by a statistically significant decrease in adult and muscle larval count, compared with the non-immunized infected control. Complete protection against both adults and larvae (100%) was achieved by IP injection of two doses of 600 ML, two weeks apart. The results suggested the feasible application of the microwave irradiation on meat for its decontamination from T. spiralis larvae. Such a method might be a promising a prophylaxis vaccine against trichinellosis in animals and/or humans.
Asunto(s)
Microondas , Trichinella spiralis/inmunología , Trichinella spiralis/efectos de la radiación , Triquinelosis/prevención & control , Administración Oral , Animales , Bioensayo , Modelos Animales de Enfermedad , Relación Dosis-Respuesta Inmunológica , Humanos , Inyecciones Intraperitoneales , Larva , Ratones , Microscopía Electrónica de Rastreo/métodos , Músculo Esquelético/parasitología , Resultado del Tratamiento , Trichinella spiralis/ultraestructura , Triquinelosis/inmunología , Vacunas de Productos Inactivados/inmunologíaRESUMEN
The efficacy of Clorsulon (CLS) against experimental schistosomiasis mansoni, using Praziquantel (PZQ) as a therapeutic control was evaluated. Swiss Albino mice were divided into infected non-treated control, PZQ-treated group given a single dose of 500 mg/kg four weeks post infection (PI), and infected mice treated with single, double, and triple doses of 5 mg/kg CLS per dose, one week apart starting from the 4th week PI. All animals were perfused for adults count. Parts of livers and intestines were examined for granulomata number and sizes. Pathological changes in hepatic parenchyma by H&E and Masson trichrome stains were also examined. Results revealed that a single treatment with PZQ caused a significant percentage reduction (%R) of worm load (92.68%), mean egg count in liver and intestine (91.20 & 94.01% respectively), and mean size of liver granulomata was reduced (92.06%). Regarding CLS, the worm burden was reduced proportionally with number of doses given; 87.80, 96.34 & 97.56% in single, double and triple exposures successively. Egg count in liver was decreased by 85.90, 97.01 & 96.23% respectively in treated mice. Number of intestinal granulomata was decreased by 85.28, 94.24 & 95.49% in a similar way. Size of hepatic granulomata was decreased by 89.02, 94.51 & 95.05% by 1, 2 & 3 doses consecutively. All parameters reflected non significant difference between 2 & 3 dose of CLS. The results were critically discussed.
Asunto(s)
Antihelmínticos/uso terapéutico , Schistosoma mansoni/efectos de los fármacos , Esquistosomiasis mansoni/tratamiento farmacológico , Sulfanilamidas/uso terapéutico , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Humanos , Ratones , Tamaño de los Órganos , Especificidad de Órganos , Recuento de Huevos de Parásitos , Distribución Aleatoria , Resultado del TratamientoRESUMEN
ASPP1 and ASPP2 are both proteins that interact with p53 and enhance its ability to induce apoptosis by selectively elevating the expression of proapoptotic p53-responsive genes. iASPP(RAI) is a third member of the family that is the most conserved inhibitor of p53-mediated apoptosis. Here, we have described iASPP, a longer form of iASPP(RAI), which at 828 amino acids is more than twice the size of iASPP(RAI). Using two antibodies that recognize both iASPP and iASPP(RAI), we report that this longer form of iASPP is the predominant form of the molecule expressed in cells. Like iASPP(RAI), iASPP also binds to p53 and inhibits apoptosis induced by p53 overexpression. However, whereas iASPP(RAI) is predominantly nuclear, the N-terminus of iASPP is entirely cytoplasmic, and the longer iASPP is located in both the cytoplasm and the nucleus. The effect upon subcellular localization of the longer N-terminus of iASPP means that this new, longer form of the molecule may be subject to greater regulation and provides another layer in the control of p53-induced apoptosis.